Novelty:
New LAPC4-CR cell line which shows properties of castration resistant tumors, both in vitro and in vivo.
Value Proposition:
Technical Details:
Johns Hopkins researchers derived the LAPC4-CR androgen independent cell line from from an androgen dependent cell line model of prostate cancer, which was originally developed in the laboratory of Dr. Charles Sawyers (Nat Med. 1997 Apr;3(4):402-8). Through passaging in castrate animals and serial culturing in medium containing no androgens, they were able to generate these androgen independent sublines. In contrast to the parental cell lines, these newly derived cells grow in the absence of androgens.
Looking for Partners:
To develop and commercialize this technology as a research tool to investigate mechanisms involved in castration resistant prostate cancer.
Publications/Associated Cases:
C12051